MedTrace Logo

An Exploratory Study of A-337 in the Management of Malignant Solid Dose Escalation and Expansion Phases

NCT06093698 · Status: NOT_YET_RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 94

Last updated 2023-10-23

No results posted yet for this study

Summary

Title: An Exploratory Study of A-337 in the Management of Malignant Solid Dose Escalation and Expansion Phases

Conditions

  • Recurrent or Metastatic Solid Tumors

Interventions

BIOLOGICAL

Recombinant Anti-EpCAM-CD3 Antibody Injection

Intravenous Infusion

Sponsors & Collaborators

  • ITabMed Co., Ltd.

    lead INDUSTRY

Principal Investigators

  • Qinghua Zhou, Doctor · West China Hospital

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-12-01
Primary Completion
2026-06-30
Completion
2026-12-31

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06093698 on ClinicalTrials.gov